Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: A meta-analysis

Oncologist

Volumn 17, Issue 6, 2012, Pages 813-822

  Soranna, Davide ^a   Scotti, Lorenza ^a   Zambon, Antonella ^a   Bosetti, Cristina ^c   Grassi, Guido ^b   Catapano, Alberico ^d   La Vecchia, Carlo ^c,d,e   Mancia, Giuseppe ^b   Corrao, Giovanni ^a  

^a Unitàdi Biostatistica ed Epidemiologia   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

Cancer; Diabetes; Meta analysis; Metformin; Oral antidiabetic therapy; Sulfonylurea

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA;

BREAST CANCER; CANCER LOCALIZATION; CANCER RISK; COLORECTAL CANCER; DISEASE ASSOCIATION; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SYSTEMATIC REVIEW;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 84862848716     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0462     Document Type: Review

References (56)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-1431.
2. Noto H, Tsuijmoto T, Takehiko S et al. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocr Pract 2011;17:616-628.
3. Hernandez-Diaz S, Adami H-O. Diabetes and cancer risk: causal effects and other possible explanations. Diabetologia 2010;53:802-808.
4. Stolar MW, Hoogwerf BJ, Gorshow SM et al. Managing type 2 diabetes: going beyond glycaemic control. J Manag Care Pharm 2008;14(5 suppl B):S2-S19.
5. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385-411.
6. Barclay AW, Petocz P, McMillan-Price J et al. Glycemic index, glycemic load, and chronic disease risk-a meta-analysis of observational studies. Am J Clin Nutr 2008;87:627-637.
7. Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer 2011;18:R125-R147.
8. Holly JMP, Gunnell DJ, Davey Smith G. Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer? J Endocrinol 1999;162:321-330.
9. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011;9:33.
10. Anisimov VN, Egormin PA, Berstein LM. Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med 2005;139:721-723.
11. Berstein LM. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett 2005;224:203-212.
12. Zakikhani M, Dowling R, Fantus IG et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-10273.
13. Stolzenberg-Solomon RZ, Graubard BI, Chari S et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005;294:2872-2878.
14. Buzzai M, Jones RG, Amaravadi RK et al. Systematic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumour cell growth. Cancer Res 2007;67:6745-6752.
15. Wong AK, Howie J, Petrie JR et al. AMP-activated protein kinase pathway: potential therapeutic target in cardiometabolic disease. Clin Sci (Lond) 2009;116:607-620.
16. Decensi A, Puntoni M, Goodwin P et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3: 1451-1461.
17. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011;54:25-31.
18. Jalving M, Gietema JA, Lefrandt JD et al. Metformin: taking away the candy for cancer? Eur J Cancer 2010;46:2369-2380.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
20. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-129.
21. Higgins JPT, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003;327: 557-560.
22. Egger M, Smith DG, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
23. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004;127:1044-1050.
24. Oliveria SA, Koro CE, Yood MU et al. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndrome: Clin Res Rev 2007;2:47-57.
25. Murtola TJ, Tammela TL, Lahtela J et al. Antidiabetic medication and prostate cancer risk: a populationbased case-control study. Am J Epidemiol 2008;168: 925-931.
26. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777.
27. Li D, Yeung SC, Hassan MM et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-488.
28. Libby G, Donnelly LA, Donnan PT et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-1625.
29. Bodmer M, Meier C, Krähenbühl S et al. Longterm metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304-1308.
30. Bowker SL, Yasui Y, Veugelers P et al. Glucoselowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 2010;53:1631-1637.
31. Donadon V, Balbi M, Mas MD et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010;30: 750-758.
32. Hassan MM, Curley SA, Li D et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010;116:1938-1946.
33. Landman GW, Kleefstra N, van Hateren KJ et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010;33: 322-326.
34. Azoulay L, Dell'Aniello S, Gagnon B et al. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 2011;20:337-344.
35. Bosco JL, Antonsen S, Sørensen HT et al. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 2011; 20:101-111.
36. Lee MS, Hsu CC, Wahlqvist ML et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011;11:20.
37. Monami M, Colombi C, Balzi D et al. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011;34:129-131.
38. Tseng CH. Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 2011;34:616-621.
39. Yang X, So WY, Ma RC et al. Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 2011; 34:375-380.
40. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 2007;86:836s-842s.
41. Hsu IR, Kim SP, Kabir M et al. Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr 2007;86:s867-s871.
42. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007;132: 2208-2225.
43. Garmendia ML, Pereira A, Alvarado ME et al. Relation between insulin resistance and breast cancer among Chilean women. Ann Epidemiol 2007;17:403-409.
44. Grote VA, Becker S, Kaaks R. Diabetes mellitus type 2-an independent risk factor for cancer? Exp Clin Endocrinol Diabetes 2010;118:4-8.
45. Pisani P. Hyper-insulinaemia and cancer, metaanalyses of epidemiological studies. Arch Physiol Biochem 2008;114:63-70.
46. Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu Rev Biochem 2006; 75:137-163.
47. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007;100:328-341.
48. Steinberg GR, Macaulay SL, Febbraio MA et al. AMP-activated protein kinase-the fat controller of the energy railroad. Can J Physiol Pharmacol 2006;84:655-665.
49. Palacios OM, Carmona JJ, Michan S et al. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. Aging (Albany NY) 2009;1:771-783.
50. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003;115:577-590.
51. Bowker SL, Majumdar SR, Veugelers P et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-258.
52. Monami M, Luzzi C, Lamanna C et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006;22:477-482.
53. Monami M, Balzi D, Lamanna C et al. Are sulfonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007;23:479-484.
54. Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet 2009;374:511-513.
55. La Vecchia C. Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk. Metabolism 2011;60:1357-1358.
56. Aguilar D, Chan W, Bozkurt B et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 2011;4:53-58.